¿Qué hacer? | 12 MAY 09

Trastornos por consumo de alcohol

Son comunes y potencialmente letales en una amplia gama de enfermedades médicas y psiquiátricas.
Autor/a: Marc A Schuckit. Fuente: Department of Psychiatry, University of California, San Diego, CA, USA; VA San Diego Healthcare System, San Diego, CA, USA Alcohol-use disorders. The Lancet, 373 (9662):492 - 501, 7 February 2009
INDICE:  1.  | 2. Bibliografía
Bibliografía

Referencias

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders—text revision (DSM-IV). 4th edn. Washington, DC, USA: American Psychiatric Association, 2000.
2. WHO. ICD-10 classifi cation of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva, Switzerland: World Health Organization, 1992.
3. Schuckit MA. Drug and alcohol abuse: a clinical guide to diagnosis and treatment, 6th edn. New York, USA: Springer, 2006.
4. Teesson M, Baillie A, Lynskey A, Manor B, Degenhardt L. Substance use, dependence and treatment seeking in the United States and
5. Australia: a cross-national comparison. Drug Alcohol Depend 2006; 81: 149–55.
6. Saxena S. Alcohol, Europe, and developing countries. Addiction 1997; 92 (suppl 1): 43–48.
7. Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the future national survey results on drug use, 1975–2006: Vol 1, Secondary school students (NIH Publication No. 06-5727). Bethesda, MD, USA: National Institute on Drug Abuse, 2007.
8. Hasin DS, Stinson FS, Ogburn E, et al. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States. Arch Gen Psychiatry 2007; 64: 830–42.
9. Mertens J, Weisner C, Ray G, Fireman B, Walsh K. Hazardous drinkers and drug users in HMO primary care: prevalence, medical conditions and costs. Alcohol Clin Exp Res 2005; 29: 989–98.
10. Dawson DA, Grant BF, Stinson FS, et al, Recovery from DSM-IV alcohol dependence: United States, 2001–2002. Addiction 2005; 100: 281–92.
11. Schuckit MA, Smith TL, Danko GP, et al. Prospective evaluation of the four DSM-IV criteria for alcohol abuse in a large population, Am J Psychiatry 2005; 162: 350–60.
12. Hasin D, Grant BF, Cottler L, et al. Nosological comparisons of alcohol and drug diagnoses: a multisite, multi-instrument international study. Drug Alcohol Depend 1997; 47: 217–26.
13. Hasin D, Li Q, McCloud S, Endicott J. Agreement between DSM-III, DSM-III-R, DSM-IV and ICD-10 alcohol diagnoses in US community-sample heavy drinkers. Addiction 1996;91: 1517–27.
14. Rush AJ Jr, Pincus HA, First MB, et al. Handbook of Psychiatric Measures: Task Force for the Handbook of Psychiatric Measures. Washington, DC, USA: American Psychiatric Association, 2000.
15. Saremi A, Hanson RL, Williams DE, et al. Validity of the CAGE questionnaire in an American Indian population. J Stud Alcohol 2001; 62: 294–300.
16. Reinert DF, Allen JP. The alcohol use disorders identifi cation test: an update of research fi ndings. Alcohol Clin Exp Res 2007; 31: 185–99.
17. Berner MM, Kriston L, Bentele M, Harter M. The Alcohol Use Identifi cation Test for detecting at-risk drinking: a systematic review and meta-analysis. J Stud Alcohol Drugs 2007; 68: 461–73.
18. Hietala J, Kiovisto H, Anttila P, Niemela O. Comparison of the combined marker GGT-CDT and the conventional laboratory markers of alcohol abuse in heavy drinkers, moderate drinkers and abstainers. Alcohol Alcohol 2006; 41: 528–33.
19. Parker AJR, Marshall EJ, Ball DM. Diagnosis and management of alcohol use disorders. BMJ 2008; 336: 496–501.
20. Irwin M, Baird S, Smith T, Schuckit MA. Use of laboratory tests to monitor heavy drinking by alcoholic men discharged from a treatment  program. Am J Psychiatry 1988; 145: 595–99.
21. Conigrave KM, Degenhardt LJ, Whitfi eld JB, et al. CDT, GGT, and AST as markers of alcohol use: The WHO/ISBRA Collaborative Project. Alcohol Clin Exp Res 2002; 26: 332–39.
22. Anton RF, Youngblood M. Factors aff ecting %CDT status at entry into a multisite clinical treatment trial: experience from the COMBINE study. Alcohol Clin Exp Res 2006; 30: 1878–83.
23. Schellenberg F, Schwan R, Mennetrey L, et al. Dose-eff ect relation between daily ethanol intake in the range 0–70 grams and %CDT value: validation of a cut-off value. Alcohol Alcohol 2005; 40: 532–34.
24. Alte D, Lüdemann J, Piek M, et al. Distribution and dose response of laboratory markers to alcohol consumption in a general population: Results of the Study of Health in Pomerania (SHIP). J Stud Alcohol 2003; 64: 75–82.
25. Niemela O. Biomarkers in alcoholism. Clin Chim Acta 2007; 377: 39–49. 25 Maddrey WC. Alcohol-induced liver disease. Clin Liver Dis 2000;4: 115–31.
26. Mann K, Schafer DR, Langle G, Ackermann K, Croissant B. The long-term course of alcoholism, 5, 10 and 16 years after treatment. Addiction 2005; 100: 797–805.
27. Lemke S, Schutte K, Brennan P, Moos R. Sequencing the lifetime onset of alcohol-related symptoms in older adults: is there evidence for disease progression? J Stud Alcohol 2005; 66: 756–65.
28. Schuckit MA, Smith TL, Pierson J, et al. Externalizing disorders in the off spring from the San Diego Prospective Study of alcoholism. J Psychiatric Research 2008; 46: 644–52.
29. Babor TF, Hofmann M, DelBoca FK, et al. Types of alcoholics, I: Evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry 1992; 49: 599–608.
30. Kuperman S, Chan G, Kramer JR, et al. Relationship of age of fi rst drink to child behavioral problems and family psychopathology. Alcohol Clin Exp Res 2005; 29: 1869–76.
31. Harford T, Ye-Yi H, Hilton M. Alcohol abuse and dependence in college and noncollege samples: a ten-year prospective follow-up in a national survey. J Stud Alcohol 2006; 67: 803–09.
32. Clark DB. The natural history of adolescent alcohol use disorders. Addiction 2004; 99: 5–22.
33. Schuckit MA. Comorbidity between substance use disorders and psychiatric conditions. Addiction 2006; 101: 76–88.
34. Li T-K. The biological bases of nicotine and alcohol co-addiction. Biol Psychiatry 2007; 61: 1–3.
35. Hughes JR, Kalman D. Do smokers with alcohol problems have more diffi culty quitting? Drug Alcohol Depend 2006; 82: 91–102.
36. Maisto S, Cliff ord P, Stout R, Davis C. Drinking in the year after treatment as a predictor of three-year drinking outcomes. J Stud Alcohol 2006; 67: 823–32.
37. Bodin M, Romelsjo A. Predictors of abstinence and nonproblem drinking after 12-step treatment in Sweden. J Stud Alcohol 2006;67: 139–46.
38. Cox WM, Rosenberg H, Hazel C, et al. United Kingdom and United States healthcare providers recommendations of abstinence versus controlled drinking. Alcohol Alcohol 2004;39: 130–34.
39. Moos RF, Moos BS. Rates and predictors of relapse after natural and treated remission from alcohol use disorders. Addiction 2006; 101: 212–22.
40. Rumpf HJ, Bischof G, Hapke U, Meyer C, John U. Stability of remission from alcohol dependence without formal help. Alcohol Alcohol 2006; 41: 311–14.
41. Norstrom T. Per capita alcohol consumption and all-cause mortality in Canada, 1950–1998. Addiction 2004; 99: 1274–78.
42. Rivara FP, Garrison MM, Ebel B, McCarty CA, Christakis DA. Mortality attributable to harmful drinking in the United States, 2000. J Stud Alcohol 2004; 65: 530–36.
43. Schuckit MA, Smith TL. An evaluation of the level of response to alcohol, externalizing symptoms, and depressive symptoms as predictors of alcoholism. J Stud Alcohol 2006; 67: 215–27.
44. Timberlake DS, Hopfer CJ, Rhee SH, et al. College attendance and its eff ect on drinking behaviors in a longitudinal study of adolescents. Alcohol Clin Exp Res 2007; 31: 1020–30.
45. Nurnberger JI Jr, Bierut LJ. Seeking the connections: alcoholism and our genes. Sci Am 2007; 296: 46–53.
46. Cook TAR, Luczak SE, Shea SH, et al. Association of ALDH2 and ADH1B genotypes with response to alcohol in Asian Americans. J Stud Alcohol 2005; 66: 196–204.
47. Kendler K, Kuo PWT, Kalsi G, et al. A joint genomewide linkage analysis of symptoms of alcohol dependence and conduct disorder. Alcohol Clin Exp Res 2006; 30: 1972–77.
48. Dick DM, Bierut L, Hinrichs A, et al. The role of GABRA2 in risk for conduct disorder and alcohol and drug dependence across developmental stages. Behav Genet 2006; 36: 577–90.
49. Jones KA, Porjesz B, Almasy L, et al. A cholinergic receptor gene (CHRM2) aff ects event-related oscillations. Behav Genet 2006;36: 627–39.
50. Laucht M, Becker K, Blomeyer D, Schmidt M. Novelty seeking involved in mediating the association between the dopamine D4 receptor gene exon III polymorphism and heavy drinking in male adolescents: results from a high-risk community sample. Biol Psychiatry 2007; 61: 87–92.
51. Schuckit MA. Vulnerability factors for alcoholism. In Davis K, ed. Neuropsychopharmacology: the fi fth generation of progress. Baltimore, MD, USA: Lippincott Williams & Wilkins 2002, 1399–1411.
52. Hinckers AS, Laucht M, Schmidt MH, et al. Low level of response to alcohol as associated with serotonin transporter genotype and high alcohol intake in adolescents. Biol Psychiatry 2006; 60: 282–87.
53. Schuckit MA, Smith TL, Kalmijn J. The search for genes contributing to the low level of response to alcohol: patterns of fi ndings across studies. Alcohol Clin Exp Res 2004; 28: 1449–58.
54. Volkow N, Wang G, Begleiter H, et al. High levels of dopamine D2 receptors in unaff ected members of alcoholic families. Arch Gen Psychiatry 2006; 63: 999–1008.
55. Duranceaux NCE, Schuckit MA, Eng MY, et al. Associations of variations in alcohol dehydrogenase genes with the level of response to alcohol in non-Asians. Alcohol Clin Exp Res 2006; 30: 1470–78.
56. Dickson P, James M, Heath A, et al. Eff ects of variation at the ALDH2 locus on alcohol metabolism, sensitivity, consumption, and dependence in Europeans. Alcohol Clin Exp Res 2006; 30: 1093–1100.
57. Krystal J, Staley J, Mason G, et al. Gamma-aminobutyric acid type A receptors and alcoholism. Arch Gen Psychiatry 2006; 63: 957–68.
58. Enoch M, Schwartz L, Albaugh B, Virkkunen M, Goldman D. Dimensional anxiety mediates linkage of GABRA2 haplotypes with alcoholism. Am J Med Genet 2006; 141: 599–607.
59. Schumann G, Saam C, Heinz A, Mann K, Treutlein J. The NMDA receptor system: genetic risk factor for alcoholism. Nervenarzt 2005; 76: 1355–62.
60. Kalivas K, Volkow N. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005; 162: 1403–13.
61. van den Wildenberg E, Wiers R, Dessers J, et al. A functional polymorphism of the u-opioid receptor gene (OPRM1) infl uences cue-induced craving for alcohol in male heavy drinkers. Alcohol Clin Exp Res 2007; 31: 1–10.
62. Pastor R, Aragon C. The role of opioid receptor subtypes in the development of behavioral sensitization to ethanol. Neuropsychopharmacology 2006; 31: 1489–99.
63. Barr C, Newman T, Becker M, et al. Serotonin transporter gene variation is associated with alcohol sensitivity in rhesus macaques exposed to early-life stress. Alcohol Clin Exp Res 2005; 27: 812–17.
64. Weinshenker D, Schroeder JP. There and back again: a tale of norepinephrine and drug addiction. Neuropsychopharmacology 2007; 32:1433–1451.
65. Blednov YA, Cravatt BF, Boehn SL II, et al. Role of endocannabinoids in alcohol consumption and intoxication: studies of mice lacking fatty acid amide hydrolase. Neuropsychopharmacology 2007; 32: 1570–82.
66. Hamilton SP, Slager S, Baisre de Leon A, et al. Evidence for a genetic linkage between a polymorphism in the adenosine 2A receptor and panic disorder. Neuropsychopharmacology 2004; 29: 558–65.
67. Borgheses CM, Ali DN, Bleck V, et al. Acetylcholine and alcohol sensitivity of neuronal nicotinic acetylcholine receptors: mutations in transmembrane domains. Alcohol Clin Exp Res 2002; 26: 1764–72.
68. Witkiewitz K. Lapses following alcohol treatment: modeling and falls from the wagon. J Alcohol Drugs 2008; 69: 594–604.
69. Thomson AD, Marshall EJ. The natural history and pathophysiology of Wernicke’s encephalopathy and Korsakoff ’s psychosis. Alcohol Alcohol 2006; 41: 151–58.
70. Nelson EC, Heath AC, Bucholz KK, et al. Genetic epidemiology of alcohol-induced blackouts. Arch Gen Psychiatry 2004; 61: 257–63.
71. Pitel AL, Beaunieux H, Witkowski T, et al. Genuine episodic memory defi cits and executive dysfunctions in alcoholic subjects early in abstinence. Alcohol Clin Exp Res 2007; 31: 1169–1178.
72. Bartsch AJ, Homola G, Biller A. Manifestations of early brain recovery associated with abstinence from alcoholism. Brain 2007;130: 36–47.
73. Van Reen E, Jenni OG, Carskadon MA. Eff ects of alcohol on sleep and the sleep electroencephalogram in healthy young women. Alcohol Clin Exp Res 2006; 30: 974–81.
74. Conroy DA, Arnedt JT, Brower KJ, et al. Perception of sleep in recovering alcohol-dependent patients with insomnia: relationship with future drinking. Alcohol Clin Exp Res 2006;30: 1992–99.
75. Peters TJ, Kotowicz J, Nyka W, et al. Treatment of alcoholic polyneuropathy with vitamin B complex: a randomized controlled trial. Alcohol Alcohol 2006; 41: 636–42.
76. Fatjó F, Sancho-Bru P, Fernández-Solá J, et al. Up-regulation of myocardial L-type Ca2+ channel in chronic alcoholic subjects without cardiomyopathy. Alcohol Clin Exp Res 2007; 31: 1099–105.
77. Uyarel H, Ozdol C, Gencer AM, Okmen E, Cam N. Acute alcohol intake and QT dispersion in healthy subjects. J Stud Alcohol 2005;66: 555–58.
78. Polednak AP. Recent trends in incidence rates for selected alcohol-related cancers in the United States. Alcohol Alcohol 2005;40: 234–38.
79. Ramstedt M. Alcohol and pancreatitis mortality in the population level: experiences from 14 western countries. Addiction 2004;99: 1255–61.
80. 80 Szucs S, Sarvary A, McKee M, Adany R. Could the high level of cirrhosis in central and eastern Europe be due partly to the quality
81. of alcohol consumed? An exploratory investigation. Addiction 2005; 100: 536–42.
82. Rosenbloom MJ, Sullivan EV, Sassoon SA, et al. Alcoholism, HIV infection, and their comorbidity: factors aff ecting self-rated health-related quality of life. J Stud Alcohol Drugs 2007; 68: 115–25.
83. Romero-Gomez M, Grande L, Nogales MC, et al. Chronic alcohol use enhances the hepatitis C virus load in the liver. Alcohol Research 2002; 7: 66.
84. Kaukonen JP, Luthje IN, Luthje P, et al. Acute alcohol use among patients with acute hip fractures: a descriptive incidence study in
85. southeastern Finland. Alcohol Alcohol 2006; 41: 345–48.
86. Palmieri VO, Cicco G, Minerva F, et al, Red blood cells (RBC) deformability and aggregability: alterations in alcoholism. Adv Exp Med Biol 2006; 578: 125–31.
87. Alati R, Mamun AA, Williams GM. In utero alcohol exposure and prediction of alcohol disorders in early adulthood. Arch Gen Psychiatry 2006; 63: 1009–16.
88. Kodituwakku PW, Adams CM, Hay A, et al. Letter and category fl uency in children with fetal alcohol syndrome from a community in South Africa. J Stud Alcohol 2006; 67: 502–09.
89. Stecker T, Curran GM, Han X, Booth BM. Patterns of health services use associated with Veterans Aff airs outpatient substance-use treatment. J Stud Alcohol Drugs 2007; 68: 510–18.
90. Smith TL, Volpe FR, Hashima JN, Schuckit MA. Impact of a stimulant-focused enhanced program on the outcome of alcohol- and/or stimulant-dependent men. Alcohol Clin Exp Res 1999; 23: 1772–79.
91. Bottlender M, Soyka M. Outpatient alcoholism treatment: predictors of outcome after 3 years. Drug Alcohol Depend 2005; 80: 83–89.
92. McKellar JD, Harris AH, Moos RH. Predictors of outcomes for patients with substance-use disorders fi ve years after treatment dropout. J Stud Alcohol 2006; 67: 685–93.
93. Heather N, Brodie J, Wale S, et al. A randomized controlled trial of moderation-oriented cue exposure. J Stud Alcohol 2000; 61: 561–70.
94. Carroll K, Ball S, Nich C, et al. Motivational interviewing to improve treatment engagement and outcome in individuals seeking treatment for substance abuse: a multisite eff ectiveness study. Drug Alcohol Depend 2006; 81: 301–12.
95. Vasilaki E, Hosier S, Cox M. The effi cacy of motivational interviewing as a brief intervention for excessive drinking: a meta-analytic review. Alcohol Alcohol 2006; 41: 328–35.
96. Crawford MJ, Patton R, Touquet R, et al. Screening and referral for brief intervention of alcohol-misusing patients in an emergency department: a pragmatic randomised controlled trial. Lancet 2004;364: 1334–39.
97. Moyer A, Finney JW, Swearingen CE, et al. Brief interventions for alcohol problems: a meta-analytic review of controlled investigations in treatment-seeking and non-treatment-seeking populations. Addiction 2002; 97: 279–92.
98. Mundt M, French M, Roebuck M, Manwell L, Barry K. Brief physician advice for problem drinking among older adults: an economic analysis of costs and benefi ts. J Stud Alcohol 2005; 66: 389–94.
99. Babor T, Higgins-Biddle J, Dauser D, et al. Brief interventions for at-risk drinking: patient outcomes and cost-eff ectiveness in managed care organizations. Alcohol Alcohol 2006; 41: 624–31.
100. Ståhlbrandt H, Johnsson KO, Berglund M. Two-year outcome of alcohol interventions in Swedish university halls of residence: a cluster randomized trial of a brief skills training program, twelve-step-infl uenced intervention, and controls. Alcohol Clin Exp Res 2007; 31: 458–66.
101. Sannibale C, Fucito L, O’Connor D, Curry K. Process evaluation of an out-patient detoxifi cation services. Drug Alcohol Review 2005; 24: 475–81.
102. Reoux JP, Miller K. Routine hospital detoxifi cation practice compared to symptom triggered management with an objective withdrawal scale (CIWA-Ar). J Addiction 2000; 9: 135–44.
103. Lingford-Hughes AR, Welch S, Nutt DJ. Evidence-based guidelines for the pharmacological management of substance misuse, addition and comorbidity: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2004; 18: 293–335.
104. Humphreys K, Moos R. Encouraging posttreatment self-help group involvement to reduce demand for continuing care services: two-year clinical and utilization outcomes. Alcohol Clin Exp Res 2007; 31: 64–68.
105. Witkiewitz K Marlatt G. Relapse prevention for alcohol and drug  problems. Am Psychol 2004; 59: 224–35.
106. Moos R, Finney J, Moos B. Inpatient substance abuse care and the outcome of subsequent community residential and outpatient care. Addiction 2000; 95: 833–46.
107. Kranzler H, Koob G, Gastfriend D, Swift R, Willenbring M. Advances in the pharmacotherapy of alcoholism: Challenging misconceptions. Alcohol Clin Exp Res 2006; 30: 272–81.
108. Srisurapanont M, Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2005; 8: 267–80.
109. O’Malley SS, Garbutt JC, Gastfriend DR, Dong Q, Kranzler HR. Effi cacy of extended release naltrexone in alcohol-dependent patients who are abstinent prior to treatment. J Clin Psychopharmacology 2007; 27: 507–12.
110. Feeney G, Connor J, Young R, Tucker J, McPherson A. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres experience with pharmacotherapy. Alcohol Alcohol 2006; 41: 321–27.
111. Mason B, Goodman A, Chabac S, Lehert P. Eff ect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res 2006; 40: 383–93.
112. Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003; 60: 92–99.
113. Suh JJ, Pettinati HM, Kampman KM, O’Brien CP. The status of disulfi ram: a half of a century later. J Clin Psychopharmacol 2006; 26: 290–302.
114. Fuller FK, Gordis E. Does disulfi ram have a role in alcoholism treatment today? Addiction 2004; 99: 21–24.
115. Gelernter J, Gueorgulieva R, Kranzler HR, et al. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res 2007; 31: 555–63.
116. Krishnan-Sarin S, Krystal JH, Shi J, et al. Family history of alcoholism infl uences naltrexone-induced reduction in alcohol drinking. Biol Psychiatry 2007; 62: 694–97.
117. Mann K, Lehert P, Morgan MY. The effi cacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 2004; 28: 51–63.
118. Krampe H, Stawicki S, Wagner T, et al. Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome. Alcohol Clin Exp Res 2006; 30: 86–95.
119. Verge C, Lucena MI, López-Torres E, et al. Adverse hepatic reactions associated with calcium carbimide and disulfi ram therapy: is there still a role for these drugs? World J Gastroenterol 2006; 21: 5078–80.
120. Ho MP, Yo CH, Liu CM, Chen CL, Lee CC. Refractive hypotension in a patient with disulfi ram-ethanol reaction. Am J Med Sci 2007; 333: 53–55.
121. Johnson BA, Koob GF, Schuckit MA, et al. Understanding and treating alcohol dependence. Alcohol Clin Exp Res 2006; 30: 567–84.
122. Steensland P, Simms JA, Holgate J, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. PNAS 2007; 104: 12518–23.
123. Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007;
124. 298: 1641–51.

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024